Mallinckrodt plc announced three appointments to the company's senior management team. Hugh O'Neill has joined the company and will serve as Senior Vice President and President of Specialty Pharmaceuticals. Most recently, Mr. O'Neill held various commercial leadership positions at Sanofi, including Vice President, Commercial Excellence; General Manager; President of Sanofi Canada; and Vice President of Market Access and Business Development.

He has also been in positions of leadership at Sandoz Pharmaceuticals, Forest Laboratories, Novartis Pharmaceuticals, and Pfizer. Gary Phillips has joined the company as Senior Vice President and Chief Strategy Officer, overseeing Strategy, Portfolio Management, Business Development and Licensing, Market Analytics and Alliance Management. Most recently, Dr. Phillips was head of Global Health and Healthcare Industries for the World Economic Forum in Geneva, Switzerland.

Prior to that, he was President of Reckitt Benckiser Pharmaceuticals North America and President of US Pharmaceuticals and Surgical at Bausch & Lomb. He has also been in positions of leadership at Merck Serono, Novartis Pharmaceuticals, Wyeth-Ayerst, and Gensia Pharmaceuticals. Mario Saltarelli has joined the company as Senior Vice President and Chief Science Officer, and will lead the recently consolidated functions of Research and Development (R&D), Medical Affairs, and Regulatory Affairs.

Dr. Saltarelli comes to Mallinckrodt having recently served as Senior Vice President, R&D, at Shire plc. Prior to that, he held positions of responsibility in R&D at Abbott Laboratories and Pfizer, and academic posts in the Department of Neurology at the Emory University School of Medicine in Atlanta.